As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
The plan will allow Medicare to negotiate lower prices on as many as 250 drugs and also apply those discounts to private health plans.Health and Scienceread more
The U.S. economy will have a tough time at the start of 2020, says the head of one of the largest bond managers in the world.Delivering Alpharead more
President Donald Trump on Thursday filed a lawsuit against Manhattan District Attorney Cyrus Vance Jr. and his longtime accounting firm Mazars.Politicsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
A new Hollister store is coming later this month to New York, right down the block from Macy's, Target and Victoria's Secret in the busy Herald Square shopping district.Retailread more
Newly public ride-sharing companies Uber and Lyft have tumbled 25% since their initial public offerings, but Light Street's Glen Kacher still believes there's a path for...Delivering Alpharead more
The Federal Reserve has calmed the overnight funding market and brought its fed funds rate back in line with its target.Market Insiderread more
The PSA features kids in what initially appears to be a cheerful spot. But it becomes darker as children show how their "back to school" products help in the context of a...Politicsread more
As the Federal Reserve cuts rates, that could make it more difficult for retirees to earn income on their investments and preserve capital. A new ranking takes a look at which...Personal Financeread more
The Fed cut interest rates by a quarter point, but it also reaffirmed its rate cut was meant to serve as insurance for the economy.Market Insiderread more
The outrage over Mylan's price hikes of its lifesaving EpiPen may be mostly baked into the stock at this point, says one analyst.
The pharmaceutical company has come under fire for rapidly increasing the price of its EpiPen. On Wednesday, Mylan CEO Heather Breschappeared before members of the House Committee on Oversight and Government Reform.
While it's "certainly clear that there will be negative impact going forward," Elliot Wilbur, senior research analyst at Raymond James, said that the bad news "is largely priced into the equity" at this point.
The stock, which traded near $42.72 on Thursday, is hovering near the low end of its 52-week range. Mylan shares last hit a 52-week intraday low of $37.59 in October. The stock's current valuation is near historical levels "from which shares have outperformed the S&P," Wilbur said.
He also said a generic version of the EpiPen would lead to "essentially the entire market" converting. Wilbur said that if Teva Pharmaceuticals does get its own generic version approved, it "could probably capture 25 to 30 percent of the EpiPen market." He estimated that Teva would price its product at a 15 to 20 percent discount.
Disclosure: Raymond James & Associates makes a market in shares of Mylan.